Ulcerative Colitis

Seres Therapeutics in Cambridge, Massachusetts, is one of the recipients.

Studies have shown that the use of oral corticosteroids in patients with UC is associated with higher rates of adverse effects and use of healthcare resources compared with biologics or immunosuppressants. However, there is little research focusing on the economic and clinical burden of chronic corticosteroid use among people living with UC.

Study authors hypothesized that factors such as depression, IBD medications, and stomach or rectal surgery may play a role in the increased risk of erectile dysfunction in patients with IBD.

A recent study found all women with a first-time perinatal depression diagnosis or who had been prescribed an antidepressant from the estimated date of conception to one year postpartum.

Janssen Biotech's Remicade (infliximab), an FDA-approved tumor necrosis factor inhibitor since 1998 for Crohn's disease, has gained additional approvals for managing ulcerative colitis and rheumatoid arthritis.

The American Gastroenterological Association recommendations do not take a stand for or against using probiotics for those with intermittent pouchitis.

Inflammatory bowel disease (IBD) clinical trials often involve participants getting numerous endoscopies. Cutting back on the number of endoscopies and using noninvasive tests instead was one of the ideas discussed for how to improve clinical trial design.

In an effort to reduce financial and other quality of life burdens for individuals living with ulcerative colitis, Hongliang Chen and his colleagues from the Department of Gastroenterology and Hepatology at four medical centers in northeast China sought to develop a routine blood-based tool for assessing the extent and severity of ulcerative colitis.

Ayble Health says it provides personalized nutrition and psychology services, Higher-risk patients will have expedited scheduling with Mayo Clinic multidisciplinary experts.

For patients with ulcerative colitis, levels of C-reactive protein, leukocytes, neutrophils, eosinophils, and platelets were significantly higher compared with controls three years before diagnosis.

Chronic systemic inflammation is believed to play a significant role in the association between inflammatory bowel disease and increased risk of arrhythmias.

Mirikizumab — now with the brand name — Omvoh is the first therapy that targets interleukin-23p19, which plays a role in inflammation. It has a list price of $9,593 per month for the IV formulation and $10,360 per subcutaneous administration.

Celltrion’s Zymfentra is subcutaneous version of infliximab.

Velsipity is the second S1P receptor modulator approved by the FDA to treat patients with moderate-to-severe ulcerative colitis. The wholesale acquisition cost is $6,164 for a 30-day supply.

The new chief scientific officer of the Crohn’s and Colitis Foundation talked about the search for what triggers the chronic inflammation of Crohn’s disease and ulcerative colitis.

The new chief scientific officer of the Crohn’s and Colitis Foundation talked about what motivated him to pursue a career researching and taking care of Crohn’s and colitis patients.

Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.

Research has shown that patients with inflammatory bowel disease, including ulcerative colitis, treated with TNF-alpha blockers have a lower antibody response and a shorter duration of immunity than those who receive integrin receptor antagonists, such as Entyvio (vedolizumab), or no medication at all.

In an observational cohort study published in the September 2023 issue of The Lancet, Jiangwei Sun, Ph.D., from the Karolinska Institutet in Stockholm, Sweden, and his colleagues compared statin users with non-statin users to determine the risk of colorectal cancer in patients with IBD.

The submissions to both the FDA and the EMA are supported by two phase 3 trials demonstrating Skyrizi achieved the primary endpoint of clinical remission.

About 20% to 30% of patients with ulcerative colitis will experience acute severe ulcerative colitis in their lifetime.

A small, open-label study seeds the idea that IL-2 in low doses might be another avenue for treating ulcerative colitis. Low doses may bolster anti-inflammatory T regulatory cells (Tregs) that are believed to lack sufficient expansion in the disease.

70% of inflammatory bowel disease patients managed by in-system specialty pharmacies were adherent to their therapies, according to research findings.

Results reported in the New England Journal of Medicine show that the Eli Lilly drug was superior to placebo in keeping ulcerative colitis in remission.

The favorable results from the 84-patient study may, in part, depend on some of the definitions used.

Legislation designed to smooth the path to exemptions from step therapy has been incorporated into the Pharmacy Benefit Reform Act, one of several bills targeting pharmacy benefit managers that is making legislative headway in the Senate.

Findings by Swedish team of investigators could help identify biomarkers that would predict the response to treatments.